Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Diet Modification in pAtients With Luminal Early Breast Cancer Candidate for Primary Surgery (MACS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04469296
Recruitment Status : Not yet recruiting
First Posted : July 14, 2020
Last Update Posted : September 16, 2020
Sponsor:
Information provided by (Responsible Party):
Institut du Cancer de Montpellier - Val d'Aurelle

Brief Summary:

to analyze the feasibility for patients with early luminal breast cancer to be compliant with a diet modification - ketogenic or proteins restricted diet - during 9 +/- 1 days, before breast cancer surgery.

It's a Pilot study, monocentric, randomized


Condition or disease Intervention/treatment Phase
Breast Cancer Surgery Dietary Supplement: iso-caloric ketogenic diet Dietary Supplement: protein restricted diet Not Applicable

Detailed Description:

Many patients are modifying their diet after the diagnosis of cancer. There is a supposedly benefit, among the general public, of starving cancer cells with several diet deprivations.

Due to the lack of coherent scientific data, no evidence base recommendations can be made regarding the optimal diet during cancer and its effect on cancer growth.

The objective of this trial is to analyze the feasibility for patients with early luminal breast cancer to be compliant with a diet modification - ketogenic or proteins restricted diet - during 9 +/- 1 days, before breast cancer surgery.

The primary objective of the trial is to evaluate the compliance to the proposed diet.

The study will be conducted in patients with luminal early breast cancer, candidate to primary surgery, in order to study an homogeneous population of patients, with good performance status and without nutritional deprivation.

Metabolic changes on the main metabolic pathways and the potential antitumor effects related to these metabolic changes following the diet will be analyzed as secondary objectives of the study. We hope to find biological hypotheses to further test in a next larger prospective trial.

The impact of the patient's beliefs, anxiety and/or depression on the compliance will be analyzed as well.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Trial Studying the Feasibility of a Diet Modification in pAtients With Luminal Early Breast Cancer Candidate for Primary Surgery
Estimated Study Start Date : January 2021
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : May 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
No Intervention: control arm
In the control arm, patients will continue their usual diet without further recommendation.
Experimental: specific diet arm "Ketogenic arm"
In the specific diet arms, the study diet will be calculated with a dietician, for the ketogenic diet, an iso-caloric ketogenic will be proposed and explained to the patient Each diet will be respected by the patient during 9 days +/- 1 day.
Dietary Supplement: iso-caloric ketogenic diet
Each patient will be offered a daily diet plan that includes the different groups of low glycemic index foods to bring to each meal and snack, with the notion of quantity. Carbohydrate-free foods can be consumed ad libitum. Dietary advice will be given to increase the consumption of lipid foods (vegetable oils, butter, cheeses, fatty fish, etc.) so that 65% of the total energy intake is provided by lipids. In addition, a list of unauthorized sugars and sweeteners substitutes will be proposed as well as a low glycemic index food composition table centered on carbohydrates for better control of food choice

Experimental: specofoc diet arm "protein restricted diet"

In the specific diet arms, the study diet will be calculated with a dietician, for the protein restricted diet, a 20% protein restriction as compared to the usual diet will be calculated and the diet will be explained to the patient.

Each diet will be respected by the patient during 9 days +/- 1 day.

Dietary Supplement: protein restricted diet
A diet reducing by 20% the amount of protein compared to the usual intake of the patient will be proposed. This new ration will be carried out by calculating the proportion of total energy intake provided by the amount of protein reduced by 20% compared to the usual intake, and by modifying lipid and carbohydrate intakes to obtain an isocaloric ration.




Primary Outcome Measures :
  1. study of the compliance of patients to the two proposed diets. The proportion of compliant patients to the proposed diet according to the dietary survey realized during 3 days [ Time Frame: during 3 days before the primary surgery ]
    A patient is considered compliant to the diet if the caloric intake is equal +/- 25% to the caloric intake of the proposed diet AND For the ketogenic diet : the carbohydrate intake is equal +/- 25% to the carbohydrate intake of the proposed diet; i.e. a carbohydrate intake between 7.5 and 12.5% of the total energy intake For the protein restricted diet, the protein intake is equal +/- 25% to the protein intake proposed for this diet; i.e. a reduction between 15 and 25% compared to the previous protein intake


Secondary Outcome Measures :
  1. study of the molecular consequences of diet modifications on cancer cells and their microenvironment [ Time Frame: At the inclusion visit and the day of surgery ]
    analyse markers of cell proliferation in cancer and immune cells with blood sample and tumor sample. Evaluation of markers involved in carbohydrate mitochondrial and lipid metabolism, and markers of the Pi3K-Akt-mTOR and the IGF-R pathways

  2. study of the molecular consequences of diet modifications on cancer cells and their microenvironment [ Time Frame: At the inclusion visit and the day of surgery ]
    determine the activity of the anti-tumoral immune surveillance with blood sample and tumor sample. Correlation between the cancer response and antitumoral immune with diet programm

  3. evaluation of patient's tolerability to those diet modifications, in terms of weight status [ Time Frame: From the inclusion visit until the Day 45 post surgery ]
    Weight surveillance (in kilograms)

  4. evaluation of patient's tolerability to those diet modifications, in terms of adverse events [ Time Frame: From the inclusion visit until the Day 45 post surgery ]
    monitoring of adverse events related to diet (with CTCAE (Common Terminology Criteria for Adverse Events) version 5.0)

  5. assessment of the acceptance of study participation and reasons for refusal [ Time Frame: During 45 days before the surgery ]
    Rate of patients who agreed to participate in the study compared to the total number of patients to whom the study was proposed. Collection of reasons for refusing to participate to the study

  6. determination of the impact of diet modification on patient's quality of life [ Time Frame: From the inclusion visit until the Day 45 post surgery ]
    Result of the EORTC QLQ-C30 questionnaire (European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire) questionnaire

  7. evaluation of the impact of patient's beliefs about diet and cancer on the compliance to the proposed diet. [ Time Frame: at the inclusion visit ]
    Result of the questionnaire of Beliefs about diet and cancer OPINELE (Opinions concernant l'alimentation, la santé et le cancer)

  8. evaluation of the impact of the patient's anxiety and depression level on the compliance to the proposed diet [ Time Frame: From the inclusion visit until the Day 45 post surgery ]
    Scores obtained on the HADS scale (Hospital Anxiety and Depression Scale) (if score or = 9, result is no significant, if sore is between 10 and 12, result is limit, if result is > or = 13, result is significant



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women 18 to 80 years old
  • Invasive breast carcinoma, non-metastatic, stage I to III, pathologically proven, ER and/or PR positive, HER2 negative (luminal)
  • No treatment yet for the current breast cancer
  • Candidate for primary surgery
  • Body mass index (BMI) between 18.5 and 30 for women up to 70 years old and between 21 and 30 for women between 70 and 80 years old.
  • For patient ≥ 70 years, score of the Oncodage G8 questionnaire > 14 (if score ≤ 14, consultation with an oncogeriatrician required to validate the possibility of following a diet
  • No addiction (alcohol, tobacco, drug) that modifies the metabolism (alcohol : ≤ 2 glasses/d or ≤10 glasses/week ; tobacco : only occasional or stopped for ≥ 6 months)
  • Performance status 0-1
  • Fasting blood test :

Blood cell counts : Neutrophils > 1000/µL, Platelets > 100 000/µL, Hb > 11g/dL Hepatic biology: GOT, GPT, GGT, Phosphatases alcalines < 2x normal value Renal function : clearance > 60 mL /min Lipid profile : Total cholesterol < 1.5 x normal value, HDL>0.35g/L, LDL < 2.2 g/L (<5.7 mml/L), Triglycerides < 1.5 x normal value Fasting blood glucose < 1.26 g/l Measurement of electrolytes: Potassium, Sodium, Calcium, Magnesium (according to normal laboratory values)

  • ECG with a QTc interval ≤ 450 msec
  • Patient able to understand, participate and give a written consent for participation to the study

Exclusion Criteria:

  • Metabolic disease or other disease impairing the metabolism analysis
  • High level athlete
  • Unintentional weight loss ≥ 5% during the last month, or 10% during the last 6 months or compared to usual weight
  • Unjustified dietary supplement (not justified by a measured deficiency) during the last month
  • Restricted of unbalanced diet (vegan diet, restricted hypocaloric, hyper or hypo protein…) during the last month
  • Practice of fasting during the last 3 months
  • Corticoids that can't be stopped or not stopped for 2 weeks
  • Mellitus diabetes (with or without insulin)
  • Hypercholesterolemia requiring a treatment
  • Invasive lobular carcinoma
  • Pregnant or breast-feeding women
  • Participation to another study with an investigational treatment during the last 30 days
  • Individuals under the protection of a conservator
  • Unaffiliated patient to Social Protection System.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04469296


Contacts
Layout table for location contacts
Contact: jean-Pierre Bleuse, MD 04 67 61 31 02 ext +33 DRCI-icm105@icm.unicancer.fr
Contact: Emmanuelle Texier 04 67 61 31 02 ext +33 DRCI-icm105@icm.unicancer.fr

Locations
Layout table for location information
France
Icm Val D'Aurelle
Montpellier, Herault, France, 34298
Contact: Veronique D'HONDT, MD         
Sponsors and Collaborators
Institut du Cancer de Montpellier - Val d'Aurelle
Investigators
Layout table for investigator information
Study Chair: Veronique D'HONDT, MD ICM Val d'Aurelle
Publications of Results:

Layout table for additonal information
Responsible Party: Institut du Cancer de Montpellier - Val d'Aurelle
ClinicalTrials.gov Identifier: NCT04469296    
Other Study ID Numbers: PROICM 2019-05 MAC
First Posted: July 14, 2020    Key Record Dates
Last Update Posted: September 16, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Institut du Cancer de Montpellier - Val d'Aurelle:
dietary survey,
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases